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Abstract: The human epidermal growth factor receptor 2 (HER2/neu) is overexpressed
in 20–30% of breast cancers and is associated with tumor growth, angiogenesis, and
development of distant metastases. Trastuzumab, an anti-HER2 monoclonal antibody, is
used for the treatment of HER2 positive breast cancer and clinical efficacy of this agent is
dependent on HER2 expression. Targeted PET imaging of HER2 with radiolabeled
trastuzumab may be used to determine HER2 expression levels and guide therapy
selection. The purpose of the current study was to evaluate a facile 89Zr-trastuzumab
preparation method that can be efficiently applied for clinical grade production. Also,
relative HER2 expression levels in orthotopic and metastatic breast cancer models were
assessed by PET imaging using the 89Zr-trastuzumab produced by this simpler method.
Keywords: HER2; PET; 89Zr; immunoPET
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1. Introduction
The human epidermal growth factor receptor 2 (HER2) is a member of the epidermal growth factor
receptor (EGFR) tyrosine kinase family [1]. Heterodimerization of HER2 with other members of the
EGFR family promotes cell proliferation, survival, and migration. HER2 gene amplification and
overexpression of HER2 protein is present in multiple malignancies including 20–30% of invasive
breast cancers [2–5]. The association of HER2 with resistance to hormone therapy, chemotherapy, and
conventional radiation therapy makes it an attractive target for breast cancer treatment [2,3,6].
Trastuzumab (HerceptinTM, Genentech, South San Francisco, CA, USA) is a monoclonal antibody
that targets the extracellular domain of HER2 and is widely used for the treatment of HER2 positive
breast cancer [7]. The standard of care for locally advanced HER2 positive breast cancer is combination
treatment with trastuzumab, chemotherapy, and radiation therapy [8]. In addition to use as a first-line
therapy, trastuzumab is used in the recurrent and metastatic settings [7]. An improvement in survival
was seen in patients with HER2 positive metastatic disease receiving trastuzumab [9,10].
Although multiple studies have confirmed that trastuzumab is beneficial for the treatment of HER2
positive breast cancer [3,7,9–11], the clinical efficacy is dependent on the level of HER2 expression [12].
Two FDA-approved techniques exist to evaluate HER2 expression level, including immunohistochemistry
(IHC) and fluorescence in situ hybridization (FISH) [13]. Discrepancies have been observed between
the two methods [14]. In addition, HER2 expression can vary over the course of therapy [15,16] and
over the course of the disease [15]. HER2 expression has been demonstrated to be discordant between the
primary lesion and distant metastatic lesions, and, moreover, may vary across metastatic lesions [17–20].
Thus, the use of repeated biopsies during the course of the disease may not be clinically feasible due to
their invasiveness and not all lesions are readily accessible to be biopsied [21]. Therefore, a method
that can reliably detect HER2 expression in individual lesions would be of critical importance in
identifying patients who benefit from HER2-targeted therapy. Molecular imaging is a potentially less
invasive solution for HER2 determination [22–26].
The development of radiolabeled antibodies and antibody fragments for cell-surface receptor
detection is an active area of research [27]. Trastuzumab has been radiolabeled with 111In, 64Cu, and 89Zr,
for in vivo SPECT and PET imaging of HER2 in xenograft models of ovarian and breast cancer [22–25].
89
Zr is an ideal radionuclide for evaluation of intact antibodies because the extended half-life of
89
Zr (74.8 h) allows for imaging at 72–120 h when antibodies begin to equilibrate in the body [28].
Multiple studies have evaluated the use of 89Zr for studying antibody biodistribution [28–32].
Dijkers et al. studied the biodistribution of 89Zr-radiolabeled trastuzumab in 14 patients with HER2+
metastatic breast cancer [28] and demonstrated the feasibility of 89Zr-trastuzumab to detect HER2
expression in vivo. They utilized a multi-step procedure with a succinylated derivative of the bifunctional
chelator, desferrioxamine B (N-sucDf), for conjugation to trastuzumab and subsequent radiolabeling
with 89Zr [33]. Recently, a simpler method of chelator-antibody conjugation chemistry was described
with the p-isothiocyanatobenzyl derivative of desferrioxamine B (Df-Bz-NCS) [34,35]. This two-step
production method may be readily applied to good manufacturing production of 89Zr-trastuzumab. The
purpose of the current study was to evaluate the facile preparation method for 89Zr-trastuzumab
production and the utility of 89Zr-trastuzumab, as prepared by this two-step production method, to
characterize HER2 expression in orthotopic and metastatic breast cancer models.
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2. Experimental Section
2.1. Flow Cytometry
MDA435/LCC6HER2/GFP/Luc (HER2+) and MDA435/LCC6Vector (HER2−) cell lines, which overexpress
and minimally express HER2/neu, respectively, were generous gifts from Dawn Waterhouse
(BC Cancer Agency, Vancouver, BC, Canada). The HER2+ cell line constitutively expresses luciferase
allowing for bioluminescent imaging in the presence of luciferin. Cells were grown in Dulbecco’s
Modified Eagle Media supplemented with 10% fetal bovine serum until 80% confluent. Cells were
harvested with Cell Dissociation Buffer (Invitrogen, Carlsbad, CA, USA), washed with PBS, and
incubated on ice with 20 μg/mL trastuzumab. After 1 h, cells were washed with PBS and
incubated with Alexa Fluor 546 goat anti-human IgG (Invitrogen) for 30 min. HER2 expression was
analyzed (30,000 events collected) with the FACSAria Flow Cytometer (Becton Dickinson, Franklin
Lakes, NJ, USA).
2.2. 89Zr Production and Antibody Labeling
89

Zr-oxalate was produced via the 89Y(p,n)89Zr transmutation reaction on the CS-15 cyclotron
(Cyclotron Corporation, Berkeley, CA, USA) as described previously [33,36]. The resulting 89Zr-oxalate
was produced with a specific-activity of 8.1–15.4 GBq/μmol (220–418 mCi/μmol). Trastuzumab was
incubated with Df-Bz-NCS (Macrocyclics, Dallas, TX, USA) in 0.1 M NaHCO3 buffer pH 9.0 at room
temperature for 30 min in a 1:5 molar ratio. The resulting product, Df-Bz-NCS-trastuzumab, was
purified via Zeba Spin Desalting Columns (Pierce Biotechnology, Rockford, IL, USA). 89Zr was
complexed with Df-Bz-NCS-trastuzumab at a ratio of 0.22 MBq/μg (6 μCi/μg) of antibody in 0.5 M
HEPES buffer pH 7.0 at 37 °C for 1 h with constant agitation on an orbital mixer. Approximately 100 µg
of antibody was used per reaction. 89Zr-trastuzumab was purified with Zeba Spin Desalting Columns
and radiochemical purity was determined by radio-TLC using a mobile phase of 50 mM DTPA and
analytical size-exclusion chromatography (Superose 12 10/300 GL, GE Healthcare, Piscataway, NJ,
USA) with 20 mM HEPES and 150 mM NaCl (pH 7.3) eluted at a flow rate of 0.75 mL/min.
Millenium 32 software (Waters, Milford, MA, USA) was used to quantify chromatograms by integration.
2.3. Immunoreactive Fraction
The immunoreactive fraction of 89Zr-trastuzumab was determined using a cell-binding assay, as
previously described by Lindmo et al. [37]. HER2+ cells were suspended in microfuge tubes at
increasing concentrations ranging from 0.5 to 5 × 106 cells in 500 μL PBS. Approximately 37 kBq/0.25 μg
of 89Zr-trastuzumab in 50 μL were added to each tube (n = 3) and agitated on an orbital mixer
for 60 minutes at 25 °C. Cells were pelleted by centrifugation, washed twice with PBS, and subsequently
counted for 89Zr activity. The specific binding was calculated as the ratio of bound radioactivity to the
total amount of administered activity and was background corrected. To determine binding specificity,
similar studies were performed with the addition of 100 μg of non-radiolabeled trastuzumab in HER2+
cells and also in HER2− cells.
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2.4. Animal Studies
4 × 106 HER2+ or HER2− cells were injected into the mammary fat pad of athymic nude mice
6–8 weeks of age. Tumors grew for 6 weeks until they reached approximately 10 mm in greatest
dimension. A metastatic model was created by injection of 2 × 106 HER2+ cells into the tail vein of
athymic nude mice as previously reported [38]. As the HER2+ cells constitutively express luciferase,
bioluminescent imaging was performed 6 weeks after tail vein injection to evaluate the development of
metastatic lesions.
2.4.1. Biodistribution Studies
In vivo biodistribution studies were performed to determine the uptake of 89Zr-trastuzumab in
HER2+ and HER2− tumors in relation to normal organs. 0.55 MBq (15 μCi)/3.75 μg of 89Zr-trastuzumab
was administered via intravenous tail vein injection. Mice were sacrificed at 24 and 96 h post-injection
by cervical dislocation and tumor and select organs were harvested. Specific uptake for each tissue was
measured with background and decay correction and expressed as % injected dose per gram of
tissue (% ID/g) as calculated by normalization to the total activity injected.
2.4.2. MicroPET/CT Studies
MicroPET/CT experiments were performed with the Inveon MicroPET/CT scanner (Siemens,
Knoxville, TN, USA). Mice were administered 89Zr-trastuzumab(3.0–3.7 MBq (80–100 μCi)/20–25 μg
in 100 μL 0.9% sterile saline) via tail vein injection when orthotopic tumors reached 10–15 mm in greatest
dimension or when bioluminescent areas were observed on the BLI scans for the metastatic model.
At 24 and 96 h post-injection, mice were anesthetized with 2% isoflurane and imaged. Static images
were collected for 20 min and co-registered with image display software (Inveon Research Workplace
Workstation, Siemens, Schenectady, NY, USA). Regions of interest were drawn and the mean
standard uptake values for tumors were determined using the formula: SUV = [(MBq/mL) × (animal
wt. (g))/injected dose (MBq)].
2.5. Immunohistochemistry
Tumors were harvested after completion of MicroPET/CT imaging studies and immediately fixed
in 10% formalin. After allowing for the radioactivity to decay to background levels, tumors were
embedded in paraffin. Five-micron sections were prepared and blocked in Dako Protein Block
(Dako, Carpinteria, CA, USA) for 30 min at room temperature. Antigen retrieval was performed in
citrate-based buffer using a pressure cooker (Biocare Medical). The sections were incubated with
rabbit polyclonal anti-HER2 primary antibody (1:200, Abcam, Cambridge, MA, USA) overnight at 4 °C
and visualized with Alexa Fluor 555-conjugated goat anti-rabbit IgG (1:200, Invitrogen). Sections
were mounted were mounted with SlowFade Gold antifade reagent with 4,6-diamidino-2-phenylindole
(DAPI) (Invitrogen) and cover slipped. Images were obtained with a Soft Imaging Solutions FVII cooled
monochrome digital camera, Peltier cooled to −10 °C (Olympus America, Center Valley, PA, USA).
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2.6. Statistical Analysis
The unpaired, two-tailed Student’s t-test was utilized for data analysis. Differences at the
95% confidence level (P < 0.05) were considered to be statistically significant.
3. Results and Discussion
3.1. Trastuzumab Conjugation, Radiolabeling, and Stability Testing
Trastuzumab was successfully conjugated to Df-Bz-NCS and radiolabeled with 89Zr. The radiolabeling
efficiency was 78.4% ± 11.3%, the radiochemical purity was 98.7 ± 1.2%, and the specific activity
was 136.9 ± 22.2 MBq/mg (3.7 ± 0.6 mCi/mg) (n = 9).
3.2. Flow Cytometry and Binding Studies
To evaluate the relative expression levels of the HER2 expression on each cell line, flow cytometry
was performed. MDA435/LCC6HER2/GFP/Luc (HER2+) cells demonstrated elevated levels of HER2
expression in comparison to MDA435/LCC6Vector (HER2−) cells which demonstrated minimal
expression (Figure 1).
Figure 1. Flow cytometric analysis of HER2/neu expression. The MDA-MB-435-HER2-luc
and MDA-MB-435 breast cancer cell lines were evaluated for HER2/neu expression.
Trastuzumab was used as the primary antibody, and FITC-conjugated goat anti-human IgG
was used as the secondary antibody. Data are shown as cell number on the ordinate access
and HER2/neu intensity on the abscissa.

The immunoreactive fraction of 89Zr-trastuzumabwas 95.6% (Figure 2A). The uptake of
89
Zr-trastuzumab was 8.5-fold greater in the HER2+ cells compared to the HER2− cells (P < 0.01)
(Figure 2B). Pre-incubation with excess unlabeled trastuzumab significantly inhibited the uptake of
89
Zr-trastuzumab in HER2+ cells (Figure 2B).
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Figure 2. Cell binding studies. (A) Plot of the (total/bound) activity versus (1/[normalized cell
concentration]), used to calculate the immunoreactive fraction of 89Zr-Df-NCS-trastuzumab
in MDA-MB-435-Her2-luc cells by extrapolation to the y-intercept; (B) Cell uptake curves
of Fraction bound versus normalized cell concentration in MDA-MB-435-Her2-luc and
MDA-MB-435-luc. A blocking dose of unlabeled trastuzumab inhibited the binding of
89
Zr-radiolabeled trastuzumab.
A

B

3.3. Biodistribution Studies
Biodistribution studies with 89Zr-trastuzumab were performed in athymic nude mice bearing
HER2+ or HER2− tumors. Uptake of 89Zr-trastuzumab in HER2+ tumors was elevated after 24 h
(26.9 ± 1.04% ID/g) and continued to remain elevated at 96 h post-injection (28.83 ± 1.33% ID/g)
resulting in tumor to muscle ratios (T/M) of 8.7 ± 1.2 and 14.5 ± 2.9, respectively. In contrast,
89
Zr-trastuzumab uptake in HER2− tumors was significantly lower at 24 h (8.40 ± 0.72% ID/g)
and 96 h (7.91 ± 0.96% ID/g) in comparison to HER2+ tumors (P < 0.001 at 24 and 96 h), resulting in
T/M of 3.0 ± 0.4 and 3.4 ± 0.6, respectively. The circulating levels of 89Zr-trastuzumab in the blood
declined from 23.6 ± 2.4% ID/g at 24 h to 14.3 ± 2.1% ID/g at 96 h (P < 0.001). Bone uptake increased
from 4.8 ± 0.5%ID/g at 24 h to 10.0 ± 1.4% ID/g at 96 h. The uptake for each selected organ at 24 and
96 h is shown in Figure 3A,B, respectively.
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Figure 3. Biodistribution of 89Zr-radiolabeled trastuzumab in MDA-MB-435-Her2-luc and
MDA-MB-435-luc orthotopic xenograft models at (A) 24 h and (B) 96 h post-injection.
Data are expressed as percent injected dose per gram ± standard deviation, n = 5 for each
time point.
(A)

(B)

3.4. Imaging Studies
MicroPET/CT imaging studies demonstrated high uptake of 89Zr-trastuzumab in HER2+ tumors when
compared to HER2− tumors at 24 h and 96 h (Figure 4A,B, respectively). The uptake in HER2− tumors
was minimally increased compared to background. The SUVmean for 89Zr-trastuzumab for HER2+ and
HER2− were 2.4 ± 0.3 and 1.4 ± 0.3 at 24 h (P = 0.003), and 3.1 ± 0.4 and 1.2 ± 0.1 at 96 h (P < 0.001),
respectively. The level of 89Zr-trastuzumab in the blood significantly decreased from 24 to 96 h
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(SUVmean 1.7 ± 0.2 and 1.2 ± 0.3, respectively) as evidenced by visualization of the decreased radioactivity
in the blood pool in the heart and the inferior vena cava. Uptake in the liver (SUVmean 0.82 ± 0.4) and
kidney (SUVmean 0.58 ± 0.3) were low compared to HER2+ tumors at 96 h.
Figure 4. Representative microPET/CT images obtained at 24 and 96 h in (A) and (B)
respectively. Tumors implanted in the right mammary fat pad of each mouse. The axial (1),
sagittal (2), and coronal (3) slices at the center of the tumor are demonstrated along with
the maximal intensity projection reconstruction (4). The scale expressed as standardized
uptake value (SUV) is demonstrated at the far right.
A

B

For the metastatic tumor model, bioluminescent imaging demonstrated the development of metastasis
in the jaw (SUVmean 2.6) and in the mid-thorax region (SUVmean 2.9). These lesions were readily
visualized by microPET/CT demonstrating the potential use of 89Zr-trastuzumab for characterizing
HER2 expression in metastatic lesions (Figure 5).
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Figure 5. Detection of Her2+ metastatic lesions. 2 × 106 MDA-MB-435-Her2-luc cells were
administered via tail vein injection. Six weeks later, bioluminescent imaging (far right panel)
demonstrated development of metastasis in the head and thoracic region. MicroPET/CT
imaging using 89Zr-radiolabeled trastuzumab was able to localize these lesions to the L jaw
and thoracic vetebral body. Shown are the axial (A), sagittal (B), and coronal (C) slices at
the center of the tumor.

3.5. Immunohistochemistry
To confirm that HER2 expression levels in tumors related to HER2 expression in vitro,
immunofluorescence staining was performed with an anti-HER2 antibody. Images were acquired
under the same conditions and displayed on the same scale to ensure that the relative brightness
observed in images reflected differences in HER2 expression level. A high level of HER2 staining
(red) was seen in the HER2+ tumors when compared with the HER2− tumors. DAPI (blue) was used
as the counterstain for the nucleus (Figure 6).
3.6. Discussion
In the current study, elevated 89Zr-trastuzumab uptake was associated with the HER2 overexpression
in breast cancer cells in both orthotopic mammary fat pad and metastatic tumor models. HER2+ tumors
were clearly distinguished from HER2− tumors by microPET/CT imaging with this agent. Elevated
89
Zr-trastuzumab uptake in HER2+ tumors in comparison to low normal tissue uptake resulted in high
resolution images with excellent contrast between the tumor and normal tissues. The circulating blood
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levels of 89Zr-trastuzumab continued to decline over 4 days while the uptake in HER2+ tumors
remained elevated.
Figure 6. Immunofluorescent staining to evaluate the relative levels of HER2/neu
expression for each tumor type. HER2/neu staining is demonstrated in red with a
counterstain for the nucleus in blue.

Previous studies utilized a multi-step procedure with a succinylated derivative of desferrioxamine B
for conjugation to trastuzumab. Vosjan et al. have reported a simple, efficient method for the radiolabeling
of antibodies with 89Zr [35]. However, this procedure has not been evaluated for 89Zr-radiolabeling of
trastuzumab. In the current study, the 89Zr-radiolabeling of trastuzumab was completed in approximately
3 h. The relative ease of the two-step procedure used in the current study makes it feasible for
incorporation into good manufacturing practice grade production and for widespread clinical use.
Both an orthotopic mammary fat pad and metastatic model was utilized in the current study.
89
Zr-trastuzumab produced with the simpler method was able to characterize HER2 expression in
tumors from the orthopic and metastatic mouse models. While previous studies utilized heterotopic
subcutaneous xenograft models for ovarian and breast cancer [24,39,40], the orthotopic model may be
more clinically relevant by mimicking the tumor microenviroment and vasculature. Our results are in
agreement with Dijkers et al., who reported an uptake value of ~33% ID/g in HER2/neu positive
hindlimb tumors. In contrast, Holland et al. reported 2.5-fold higher uptake values (~73–86% ID/g) in
subcutaneous shoulder tumors [39]. These differences may be explained by the different levels of
HER2/neu expression in the varying cell lines used between the studies and also by differences in
tumor perfusion due to the different locations of tumor growth.
The metastatic breast cancer model utilized in the current study was developed via tail vein
injection of HER2+ cells. The development of tumors was initially monitored via bioluminescent
imaging. This model is more of a measure of tumor invasiveness rather than metastasis as distant sites
are not derived from cells migrating from a primary tumor. Despite this caveat, this model was suitable
for evaluating the ability of 89Zr-trastuzumab to detect HER2 expression in distant sites of disease. The
3.3 day half-life of 89Zr is ideal for imaging full, intact antibodies (150 kDa) which require multiple
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days for equilibration as demonstrated in this study and previous studies [40]. Because 89Zr is
relatively biologically inert, 89Zr-radiolabeled antibodies have low background uptake and improved
stability in comparison to other radionuclides such as 64Cu, which is readily transchelated by liver
superoxide dismutase resulting in elevated liver uptake, or some 124I-radiolabeled compounds which
are may be dehalogenated and taken up by the thyroid. There is some residual bone uptake of
89
Zr (5–10%) which may be attributed to a slow rate of intratumoral metabolism of 89Zr-trastuzumab
leading to transmetalation of 89Zr4+ ions which are sequestered in the bone [39]. Further studies on the
metabolism of 89Zr-trastuzumab are underway by our group and others.
89
Zr-trastuzumab has significant clinical potential for the detection and characterization of lesions
for HER2 status. Confirmation of HER2 status is necessary prior to initiation of trastuzumab therapy.
Immunohistochemical staining and fluorescence-in-situ hybridization techniques from biopsy specimens
taken at initial diagnosis are the current standards for determining HER2 expression [13]. However,
tumor heterogeneity plays a significant role in breast cancer [41] and HER2 expression and gene
amplification may vary across the primary tumor. Moreover, differences in the extent of HER2
expression between the primary tumor and across metastatic lesions have been reported [17,42]. As
demonstrated in this study, PET imaging with 89Zr-trastuzumab provides a comprehensive view of the
HER2 status not only within the primary tumor, but also across metastatic lesions. PET imaging with
89
Zr-trastuzumab may assist in the stratification of patients by HER2 status for decision-making about
trastuzumab therapy. With the increased costs of healthcare, a method to select patients that benefit
from trastuzumab therapy, while avoiding the unnecessary treatment of patients with low HER2
expressing tumors could have an impact on cancer treatment.
Although beyond the scope of this study, PET with 89Zr-trastuzumab may improve the ability to
detect lesions not previously detected on routine staging studies such as CT, MRI, or bone scan. In a
feasibility study involving 14 patients with metastatic breast cancer, 89Zr-trastuzumab PET imaging
provided complementary information to CT, MRI, and bone scan [28]. Of note, 89Zr-trastuzumab PET
imaging was able to reveal previously undetected brain metastases [28]. Determination of the
sensitivity and specificity of 89Zr-trastuzumab PET imaging and correlation with HER2 status in
pathological human specimens will be challenging as it is unethical to subject patients to the
discomfort of additional unnecessary biopsies.
Quantitative pre-therapy imaging studies with 89Zr-radiolabeled trastuzumab may also provide
individualized pharmacokinetic and biodistribution information necessary to determine the optimal
dose of trastuzumab for each patient. Scouting studies with 89Zr-radiolabeled trastuzumab may provide
information regarding tumor uptake in comparison to critical normal organs allowing for maximal
tumor targeting while minimizing normal tissue toxicity. Thus, 89Zr-trastuzumab imaging can provide
this information in an efficient and safe manner, with fewer patients treated at a suboptimal dose.
4. Conclusions
The p-isothiocyanatobenzyl derivative of desferrioxamine B was utilized for radiolabeling of
trastuzumab. Although beyond the scope of this study, this two-step procedure may be easily applied
to preparation of 89Zr-radiolabeled trastuzumab for clinical use. Biodistribution and imaging studies
demonstrated comparable results to those previously reported with the succinylated deravitave of
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desferrioxamine used in preparation of 89Zr-trastuzumab. 89Zr-trastuzumab PET imaging is a non-invasive
method for characterizing HER2 expression in primary and distant lesions. This information may be
useful in selecting patients that benefit most from trastuzumab therapy.
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